Thromb Haemost 2007; 97(05): 748-754
DOI: 10.1160/TH07-01-0029
Theme Issue Article
Schattauer GmbH

Chemokines in cardiovascular risk prediction

Pål Aukrust
1  Research Institute for Internal Medicine
2  Section of Clinical Immunology and Infectious Diseases
,
Arne Yndestad
1  Research Institute for Internal Medicine
,
Camilla Smith
1  Research Institute for Internal Medicine
,
Thor Ueland
1  Research Institute for Internal Medicine
3  Section of Endocrinology
,
Lars Gullesta
4  Department of Cardiology, Rikshospitalet-Radiumhospitalet, Medical Center, University of Oslo, Oslo, Norway
,
Jan K. Damås
1  Research Institute for Internal Medicine
2  Section of Clinical Immunology and Infectious Diseases
› Author Affiliations
Financial support: This work was supported by grants from the Norwegian Council of Cardiovascular Research, Research Council of Norway, the University of Oslo, Medinnova Foundation, Rikshospitalet-Radiumhospitalet Medical Center, and Helse Sør.
Further Information

Publication History

Received 16 January 2007

Accepted after revision 15 February 2007

Publication Date:
24 November 2017 (online)

Summary

In consideration of the important role of inflammation in plaque progression and stability, recent work has focused on whether plasma markers of inflammation can non-invasively diagnose and predict coronary artery disease (CAD) and other forms of atherosclerotic disorders. Although several studies support an important pathogenic role of chemokines in atherogenesis and plaque destabilization, potentially representing attractive therapeutic targets in atherosclerotic disorders,this does not necessarily mean that chemokines are suitable parameters for risk prediction. In fact, the ability to reflect up-stream inflammatory activity, stable levels in individuals and high stability of the actual protein (e.g. long half-life and negligible circadian variation), are additional important criteria for an ideal biomarker in cardiovascular disease. Although plasma/serum levels of certain chemokines (e.g. interleukin 8 and monocyte chemoattractant protein- 1) have been shown to be predictive for future cardiac events in some studies, independent of traditional cardiovascular risk factors and C-reactive protein,and although certain gene polymorphisms of chemokines/chemokine receptors (e.g. fractalkine receptor) have been shown to be predictive of future atherosclerotic disease, further prospective studies, including a larger number patients,are needed to make any firm conclusion. While the demonstrations of an association between chemokines and CAD are a necessary first step, such studies do not establish the full clinical utility of a biomarker, which is a more demanding process that requires validation in multiple cohorts, and clear demonstration of incremental prognostic value over traditional risk models. If successful, such new biomarker will be a useful indicator for better risk assessment,diagnosis,and prognosis, as well as monitoring pharmacological treatments for atherosclerosis.